FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Equine veterinary journal2019; 51(6); 787-794; doi: 10.1111/evj.13089

The use of equine chondrogenic-induced mesenchymal stem cells as a treatment for osteoarthritis: A randomised, double-blinded, placebo-controlled proof-of-concept study.

Abstract: There is a need to improve therapies for osteoarthritis in horses. Objective: To assess the efficacy of equine allogeneic chondrogenic-induced mesenchymal stem cells combined with equine allogeneic plasma as a novel therapy for osteoarthritis in horses. Methods: Randomised, double-blinded, placebo-controlled experiment. Methods: In 12 healthy horses, osteoarthritis was induced in the metacarpophalangeal joint using an osteochondral fragment-groove model. Five weeks after surgery, horses were randomly assigned to either an intra-articular injection with chondrogenic-induced mesenchymal stem cells + equine allogeneic plasma (= intervention) or with 0.9% saline solution (= control). From surgery until the study end, horses underwent a weekly joint and lameness assessment. Synovial fluid was collected for cytology and biomarker analysis before surgery and at Weeks 5, 5 + 1d, 7, 9 and 11. At Week 11, horses were subjected to euthanasia, and the metacarpophalangeal joints were evaluated macroscopically and histologically. Results: No serious adverse events or suspected adverse drug reactions occurred during the study. A significant improvement in visual and objective lameness was seen with the intervention compared with the control. Synovial fluid displayed a significantly higher viscosity and a significantly lower glycosaminoglycan concentration in the intervention group. Other biomarkers or cytology parameters were not significantly different between the treatment groups. Significantly less wear lines and synovial hyperaemia were present in the intervention group. The amount of cartilage oligomeric matrix protein, collagen type II and glycosaminoglycans were significantly higher in the articular cartilage of the intervention group. Conclusions: This study assessed the short-term effect of the intervention on a limited number of horses, using an osteoarthritis model. This study also included multiple statistical tests, increasing the risk of type 1 error. Conclusions: Equine allogeneic chondrogenic-induced mesenchymal stem cells combined with equine allogeneic plasma may be a promising treatment for osteoarthritis in horses. The Summary is available in Spanish - see Supporting Information.
© 2019 Global International Stem cell Technology (GST) NV. Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd.
Get Full Text
Publication Date: 2019-04-13 PubMed ID: 30815897PubMed Central: PMC6850029DOI: 10.1111/evj.13089Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial
  • Veterinary

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study focuses on using mesenchymal stem cells sourced from horses, genetically modified to lead to cartilage formation, and then mixed with horse blood plasma as a potential treatment for osteoarthritis in horses.

Study Objective and Methodology

  • The researchers were keen on evaluating the effectiveness of a proposed therapy for osteoarthritis in horses, this therapy involved the use of genetically enhanced mesenchymal stem cells tied with equine blood plasma.
  • A total of 12 healthy horses were used in this randomized, double-blinded, placebo-controlled study. Healthy horses were inflicted with osteoarthritis in one specific joint. A solution composed of the modified stem cells and horse blood plasma was injected into the horses five weeks later. As a control, some of the horses were injected with a saline solution instead.
  • Throughout the course of the study, the researchers conducted weekly joint and lameness assessments. They also collected synovial fluid – the lubricating fluid in the joints – for further analysis.

Results and Observations

  • No severe adverse events or suspected negative drug reactions were witnessed throughout the duration of the study.
  • The horses who were treated with the experimental therapy showed significant improvement in their lameness compared to horses in the control group. The synovial fluid derived from the treatment group had a higher viscosity and a significantly lower concentration of glycosaminoglycan – a compound known to cause pain and inflammation when present in excessive amounts.
  • The treated horses exhibited fewer signs of joint wear and inflammation compared to the control group. Additionally, the treated horses had significantly higher levels of proteins and compounds necessary for maintaining healthy joint cartilage.

Limits and Conclusions

  • The researchers acknowledge that their study had a limited scope, treating only a limited number of horses and assessing the short-term effects of the treatment.
  • Despite its limitations, this study suggests that the combination of equine allogeneic chondrogenic-induced mesenchymal stem cells and equine allogeneic plasma may be a promising treatment for osteoarthritis in horses.

Cite This Article

APA
Broeckx SY, Martens AM, Bertone AL, Van Brantegem L, Duchateau L, Van Hecke L, Dumoulin M, Oosterlinck M, Chiers K, Hussein H, Pille F, Spaas JH. (2019). The use of equine chondrogenic-induced mesenchymal stem cells as a treatment for osteoarthritis: A randomised, double-blinded, placebo-controlled proof-of-concept study. Equine Vet J, 51(6), 787-794. https://doi.org/10.1111/evj.13089

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 51
Issue: 6
Pages: 787-794

Researcher Affiliations

Broeckx, S Y
  • Global Stem Cell Technology NV, Anacura Group, Evergem, Belgium.
  • Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Martens, A M
  • Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Bertone, A L
  • Department of Veterinary Clinical Sciences, Ohio State University, Columbus, USA.
Van Brantegem, L
  • Department of Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Duchateau, L
  • Biometrics Research Group, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Van Hecke, L
  • Global Stem Cell Technology NV, Anacura Group, Evergem, Belgium.
Dumoulin, M
  • Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Oosterlinck, M
  • Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Chiers, K
  • Department of Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Hussein, H
  • Department of Veterinary Clinical Sciences, Ohio State University, Columbus, USA.
Pille, F
  • Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Spaas, J H
  • Global Stem Cell Technology NV, Anacura Group, Evergem, Belgium.

MeSH Terms

  • Animals
  • Chondrogenesis
  • Double-Blind Method
  • Female
  • Horse Diseases / therapy
  • Horses
  • Male
  • Mesenchymal Stem Cell Transplantation / veterinary
  • Mesenchymal Stem Cells / physiology
  • Osteoarthritis / therapy
  • Osteoarthritis / veterinary
  • Proof of Concept Study

Grant Funding

  • 130543 / Global Stem cell Technology NV

References

This article includes 25 references
  1. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse - a review.. Vet J 2006 Jan;171(1):51-69.
    pubmed: 16427582doi: 10.1016/j.tvjl.2004.07.008google scholar: lookup
  2. Ferris DJ, Frisbie DD, McIlwraith CW, Kawcak CE. Current joint therapy usage in equine practice: a survey of veterinarians 2009.. Equine Vet J 2011 Sep;43(5):530-5.
    pubmed: 21668486doi: 10.1111/j.2042-3306.2010.00324.xgoogle scholar: lookup
  3. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis.. Bone Joint Res 2012 Nov;1(11):297-309.
    pmc: PMC3626203pubmed: 23610661doi: 10.1302/2046-3758.111.2000132google scholar: lookup
  4. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis.. J Orthop Res 2009 Dec;27(12):1675-80.
    pubmed: 19544397doi: 10.1002/jor.20933google scholar: lookup
  5. Wilke MM, Nydam DV, Nixon AJ. Enhanced early chondrogenesis in articular defects following arthroscopic mesenchymal stem cell implantation in an equine model.. J Orthop Res 2007 Jul;25(7):913-25.
    pubmed: 17405160doi: 10.1002/jor.20382google scholar: lookup
  6. McIlwraith CW, Frisbie DD, Rodkey WG, Kisiday JD, Werpy NM, Kawcak CE, Steadman JR. Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects.. Arthroscopy 2011 Nov;27(11):1552-61.
    pubmed: 21862278doi: 10.1016/j.arthro.2011.06.002google scholar: lookup
  7. Broeckx S, Zimmerman M, Crocetti S, Suls M, Mariën T, Ferguson SJ, Chiers K, Duchateau L, Franco-Obregón A, Wuertz K, Spaas JH. Regenerative therapies for equine degenerative joint disease: a preliminary study.. PLoS One 2014;9(1):e85917.
    pmc: PMC3896436pubmed: 24465787doi: 10.1371/journal.pone.0085917google scholar: lookup
  8. Broeckx S, Suls M, Beerts C, Vandenberghe A, Seys B, Wuertz-Kozak K, Duchateau L, Spaas JH. Allogenic mesenchymal stem cells as a treatment for equine degenerative joint disease: a pilot study.. Curr Stem Cell Res Ther 2014;9(6):497-503.
    pubmed: 25175766doi: 10.2174/1574888x09666140826110601google scholar: lookup
  9. Broeckx SY, Pille F, Buntinx S, Van Brantegem L, Duchateau L, Oosterlinck M, Chiers K, Bertone AL, Spaas JH, Martens AM. Evaluation of an osteochondral fragment-groove procedure for induction of metacarpophalangeal joint osteoarthritis in horses.. Am J Vet Res 2019 Mar;80(3):246-258.
    pubmed: 30801207doi: 10.2460/ajvr.80.3.246google scholar: lookup
  10. Committee, A.H.S. (1999) Guide to Veterinary Services for Horse Shows, 7th edn., American Association of Equine Practitioners, Lexington.
  11. Keegan KG, MacAllister CG, Wilson DA, Gedon CA, Kramer J, Yonezawa Y, Maki H, Pai PF. Comparison of an inertial sensor system with a stationary force plate for evaluation of horses with bilateral forelimb lameness.. Am J Vet Res 2012 Mar;73(3):368-74.
    pubmed: 22369528doi: 10.2460/ajvr.73.3.368google scholar: lookup
  12. McCracken MJ, Kramer J, Keegan KG, Lopes M, Wilson DA, Reed SK, LaCarrubba A, Rasch M. Comparison of an inertial sensor system of lameness quantification with subjective lameness evaluation.. Equine Vet J 2012 Nov;44(6):652-6.
    pubmed: 22563674doi: 10.1111/j.2042-3306.2012.00571.xgoogle scholar: lookup
  13. van Heel MC, Barneveld A, van Weeren PR, Back W. Dynamic pressure measurements for the detailed study of hoof balance: the effect of trimming.. Equine Vet J 2004 Dec;36(8):778-82.
    pubmed: 15656515doi: 10.2746/0425164044847993google scholar: lookup
  14. Oosterlinck M, Pille F, Back W, Dewulf J, Gasthuys F. Use of a stand-alone pressure plate for the objective evaluation of forelimb symmetry in sound ponies at walk and trot.. Vet J 2010 Mar;183(3):305-9.
    pubmed: 19217810doi: 10.1016/j.tvjl.2008.12.012google scholar: lookup
  15. McIlwraith CW, Frisbie DD, Kawcak CE, Fuller CJ, Hurtig M, Cruz A. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the horse.. Osteoarthritis Cartilage 2010 Oct;18 Suppl 3:S93-105.
    pubmed: 20864027doi: 10.1016/j.joca.2010.05.031google scholar: lookup
  16. Broeckx SY, Borena BM, Van Hecke L, Chiers K, Maes S, Guest DJ, Meyer E, Duchateau L, Martens A, Spaas JH. Comparison of autologous versus allogeneic epithelial-like stem cell treatment in an in vivo equine skin wound model.. Cytotherapy 2015 Oct;17(10):1434-46.
    pubmed: 26212608doi: 10.1016/j.jcyt.2015.06.004google scholar: lookup
  17. Auer JA, Fackelman GE, Gingerich DA, Fetter AW. Effect of hyaluronic acid in naturally occurring and experimentally induced osteoarthritis.. Am J Vet Res 1980 Apr;41(4):568-74.
    pubmed: 7406275
  18. Jann HW, Hart JC, Stein LE, Ritchey J, Blaik M, Payton M, Fackelman GE, Rezabek GB, Mann BK. The Effects of a Crosslinked, Modified Hyaluronic Acid (xCMHA-S) Gel on Equine Tendon Healing.. Vet Surg 2016 Feb;45(2):231-9.
    pubmed: 26767727doi: 10.1111/vsu.12440google scholar: lookup
  19. Palmer JL, Bertone AL, McClain H. Assessment of glycosaminoglycan concentration in equine synovial fluid as a marker of joint disease.. Can J Vet Res 1995 Jul;59(3):205-12.
    pmc: PMC1263767pubmed: 8521354
  20. Kulkarni P, Deshpande S, Koppikar S, Patil S, Ingale D, Harsulkar A. Glycosaminoglycan measured from synovial fluid serves as a useful indicator for progression of Osteoarthritis and complements Kellgren-Lawrence Score.. BBA Clin 2016 Dec;6:1-4.
    pmc: PMC4900295pubmed: 27331021doi: 10.1016/j.bbacli.2016.05.002google scholar: lookup
  21. Kaido M, Kilborne AH, Sizemore JL, Reisbig NA, Aarnes TK, Bertone AL. Effects of repetition within trials and frequency of trial sessions on quantitative parameters of vertical force peak in horses with naturally occurring lameness.. Am J Vet Res 2016 Jul;77(7):756-65.
    pubmed: 27347829doi: 10.2460/ajvr.77.7.756google scholar: lookup
  22. Spaas JH, Broeckx SY, Chiers K, Ferguson SJ, Casarosa M, Van Bruaene N, Forsyth R, Duchateau L, Franco-Obregón A, Wuertz-Kozak K. Chondrogenic Priming at Reduced Cell Density Enhances Cartilage Adhesion of Equine Allogeneic MSCs - a Loading Sensitive Phenomenon in an Organ Culture Study with 180 Explants.. Cell Physiol Biochem 2015;37(2):651-65.
    doi: 10.1159/000430384pubmed: 26344791google scholar: lookup
  23. Broeckx SY, Spaas JH, Chiers K, Duchateau L, Van Hecke L, Van Brantegem L, Dumoulin M, Martens AM, Pille F. Equine allogeneic chondrogenic induced mesenchymal stem cells: A GCP target animal safety and biodistribution study.. Res Vet Sci 2018 Apr;117:246-254.
    pubmed: 29329028doi: 10.1016/j.rvsc.2017.12.018google scholar: lookup
  24. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    pmc: PMC4055004pubmed: 24461709doi: 10.1186/scrt402google scholar: lookup
  25. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
    pmc: PMC4414005pubmed: 25889095doi: 10.1186/s13287-015-0053-xgoogle scholar: lookup

Citations

This article has been cited 27 times.
  1. Stage HJ, Trappe S, Söllig K, Trachsel DS, Kirsch K, Zieger C, Merle R, Aschenbach JR, Gehlen H. Multilineage Differentiation Potential of Equine Adipose-Derived Stromal/Stem Cells from Different Sources. Animals (Basel) 2023 Apr 15;13(8).
    doi: 10.3390/ani13081352pubmed: 37106915google scholar: lookup
  2. Mayet A, Zablotski Y, Roth SP, Brehm W, Troillet A. Systematic review and meta-analysis of positive long-term effects after intra-articular administration of orthobiologic therapeutics in horses with naturally occurring osteoarthritis. Front Vet Sci 2023;10:1125695.
    doi: 10.3389/fvets.2023.1125695pubmed: 36908512google scholar: lookup
  3. Clarke EJ, Johnson E, Caamaño Gutierrez E, Andersen C, Berg LC, Jenkins RE, Lindegaard C, Uvebrant K, Lundgren-Åkerlund E, Turlo A, James V, Jacobsen S, Peffers MJ. Temporal extracellular vesicle protein changes following intraarticular treatment with integrin α10β1-selected mesenchymal stem cells in equine osteoarthritis. Front Vet Sci 2022;9:1057667.
    doi: 10.3389/fvets.2022.1057667pubmed: 36504839google scholar: lookup
  4. Zhu Y, Fu W. Peripheral Blood-Derived Stem Cells for the Treatment of Cartilage Injuries: A Systematic Review. Front Bioeng Biotechnol 2022;10:956614.
    doi: 10.3389/fbioe.2022.956614pubmed: 35935493google scholar: lookup
  5. Soukup R, Gerner I, Gültekin S, Baik H, Oesterreicher J, Grillari J, Jenner F. Characterisation of Extracellular Vesicles from Equine Mesenchymal Stem Cells. Int J Mol Sci 2022 May 23;23(10).
    doi: 10.3390/ijms23105858pubmed: 35628667google scholar: lookup
  6. De Maré L, Boshuizen B, Vidal Moreno de Vega C, de Meeûs C, Plancke L, Gansemans Y, Van Nieuwerburgh F, Deforce D, de Oliveira JE, Hosotani G, Oosterlinck M, Delesalle C. Profiling the Aerobic Window of Horses in Response to Training by Means of a Modified Lactate Minimum Speed Test: Flatten the Curve. Front Physiol 2022;13:792052.
    doi: 10.3389/fphys.2022.792052pubmed: 35392373google scholar: lookup
  7. Knott LE, Fonseca-Martinez BA, O'Connor AM, Goodrich LR, McIlwraith CW, Colbath AC. Current use of biologic therapies for musculoskeletal disease: A survey of board-certified equine specialists. Vet Surg 2022 May;51(4):557-567.
    doi: 10.1111/vsu.13805pubmed: 35383972google scholar: lookup
  8. Depuydt E, Broeckx SY, Chiers K, Patruno M, Da Dalt L, Duchateau L, Saunders J, Pille F, Martens A, Van Hecke L, Spaas JH. Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries. Front Vet Sci 2021;8:789293.
    doi: 10.3389/fvets.2021.789293pubmed: 35281431google scholar: lookup
  9. Estrada McDermott J, Pezzanite L, Goodrich L, Santangelo K, Chow L, Dow S, Wheat W. Role of Innate Immunity in Initiation and Progression of Osteoarthritis, with Emphasis on Horses. Animals (Basel) 2021 Nov 13;11(11).
    doi: 10.3390/ani11113247pubmed: 34827979google scholar: lookup
  10. Zayed M, Adair S, Dhar M. Effects of Normal Synovial Fluid and Interferon Gamma on Chondrogenic Capability and Immunomodulatory Potential Respectively on Equine Mesenchymal Stem Cells. Int J Mol Sci 2021 Jun 15;22(12).
    doi: 10.3390/ijms22126391pubmed: 34203758google scholar: lookup
  11. Bertoni L, Jacquet-Guibon S, Branly T, Desancé M, Legendre F, Melin M, Rivory P, Hartmann DJ, Schmutz A, Denoix JM, Demoor M, Audigié F, Galéra P. Evaluation of Allogeneic Bone-Marrow-Derived and Umbilical Cord Blood-Derived Mesenchymal Stem Cells to Prevent the Development of Osteoarthritis in An Equine Model. Int J Mol Sci 2021 Mar 2;22(5).
    doi: 10.3390/ijms22052499pubmed: 33801461google scholar: lookup
  12. Ribitsch I, Oreff GL, Jenner F. Regenerative Medicine for Equine Musculoskeletal Diseases. Animals (Basel) 2021 Jan 19;11(1).
    doi: 10.3390/ani11010234pubmed: 33477808google scholar: lookup
  13. Zygmuntowicz A, Burmańczuk A, Markiewicz W. Selected Biological Medicinal Products and Their Veterinary Use. Animals (Basel) 2020 Dec 9;10(12).
    doi: 10.3390/ani10122343pubmed: 33316993google scholar: lookup
  14. Kim KH, Park TS, Cho BW, Kim TM. Nanoparticles from Equine Fetal Bone Marrow-Derived Cells Enhance the Survival of Injured Chondrocytes. Animals (Basel) 2020 Sep 23;10(10).
    doi: 10.3390/ani10101723pubmed: 32977476google scholar: lookup
  15. Ribitsch I, Baptista PM, Lange-Consiglio A, Melotti L, Patruno M, Jenner F, Schnabl-Feichter E, Dutton LC, Connolly DJ, van Steenbeek FG, Dudhia J, Penning LC. Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do. Front Bioeng Biotechnol 2020;8:972.
    doi: 10.3389/fbioe.2020.00972pubmed: 32903631google scholar: lookup
  16. Paterson YZ, Cribbs A, Espenel M, Smith EJ, Henson FMD, Guest DJ. Genome-wide transcriptome analysis reveals equine embryonic stem cell-derived tenocytes resemble fetal, not adult tenocytes. Stem Cell Res Ther 2020 May 19;11(1):184.
    doi: 10.1186/s13287-020-01692-wpubmed: 32430075google scholar: lookup
  17. Chen YR, Yan X, Yuan FZ, Ye J, Xu BB, Zhou ZX, Mao ZM, Guan J, Song YF, Sun ZW, Wang XJ, Chen ZY, Wang DY, Fan BS, Yang M, Song ST, Jiang D, Yu JK. The Use of Peripheral Blood-Derived Stem Cells for Cartilage Repair and Regeneration In Vivo: A Review. Front Pharmacol 2020;11:404.
    doi: 10.3389/fphar.2020.00404pubmed: 32308625google scholar: lookup
  18. Braucke AFGV, Frederiksen NL, Berg LC, Aarsvold S, Müller FC, Boesen MP, Lindegaard C. Identification and Quantification of Transient Receptor Potential Vanilloid 1 (TRPV1) in Equine Articular Tissue. Animals (Basel) 2020 Mar 18;10(3).
    doi: 10.3390/ani10030506pubmed: 32197454google scholar: lookup
  19. Shi L, Khan MZ, Ullah A, Liang H, Geng M, Akhtar MF, Na J, Han Y, Wang C. Advancements in Stem Cell Applications for Livestock Research: A Review. Vet Sci 2025 Apr 23;12(5).
    doi: 10.3390/vetsci12050397pubmed: 40431490google scholar: lookup
  20. Luque RM, Henderson B, McCorkell TC, Alizadeh AH, Russell KA, Koch TG, Koenig J. Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid. Equine Vet J 2025 Sep;57(5):1245-1254.
    doi: 10.1111/evj.14531pubmed: 40364589google scholar: lookup
  21. Ajeeb B, Kiyotake EA, Keefe PA, Phillips JN, Hatzel JN, Goodrich LR, Detamore MS. Comparison of the chondrogenic potential of eBMSCs and eUCMSCs in response to selected peptides and compounds. BMC Vet Res 2025 Feb 17;21(1):70.
    doi: 10.1186/s12917-024-04448-3pubmed: 39956895google scholar: lookup
  22. Liu B, Liu T, Li Y, Tan C. Innovative Biotherapies and Nanotechnology in Osteoarthritis: Advancements in Inflammation Control and Cartilage Regeneration. Int J Mol Sci 2024 Dec 13;25(24).
    doi: 10.3390/ijms252413384pubmed: 39769149google scholar: lookup
  23. Sourugeon Y, Boffa A, Perucca Orfei C, de Girolamo L, Magalon J, Sánchez M, Tischer T, Filardo G, Laver L. Cell-based therapies have disease-modifying effects on osteoarthritis in animal models: A systematic review by the ESSKA Orthobiologic Initiative. Part 3: Umbilical cord, placenta, and other sources for cell-based injectable therapies. Knee Surg Sports Traumatol Arthrosc 2025 May;33(5):1695-1708.
    doi: 10.1002/ksa.12472pubmed: 39302089google scholar: lookup
  24. Cequier A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, Serrano MB, Zaragoza MP, Romero A, Rodellar C, Barrachina L. The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility: in vivo study in the horse. Front Vet Sci 2024;11:1391872.
    doi: 10.3389/fvets.2024.1391872pubmed: 38957800google scholar: lookup
  25. Andersen C, Walters M, Bundgaard L, Berg LC, Vonk LA, Lundgren-Åkerlund E, Henriksen BL, Lindegaard C, Skovgaard K, Jacobsen S. Intraarticular treatment with integrin α10β1-selected mesenchymal stem cells affects microRNA expression in experimental post-traumatic osteoarthritis in horses. Front Vet Sci 2024;11:1374681.
    doi: 10.3389/fvets.2024.1374681pubmed: 38596460google scholar: lookup
  26. Stewart HL, Gilbert D, Stefanovski D, Garman Z, Albro MB, Bais M, Grinstaff MW, Snyder BD, Schaer TP. A missed opportunity: A scoping review of the effect of sex and age on osteoarthritis using large animal models. Osteoarthritis Cartilage 2024 May;32(5):501-513.
    doi: 10.1016/j.joca.2024.02.009pubmed: 38408635google scholar: lookup
  27. Andersen C, Jacobsen S, Uvebrant K, Griffin JF 4th, Vonk LA, Walters M, Berg LC, Lundgren-Åkerlund E, Lindegaard C. Integrin α10β1-Selected Mesenchymal Stem Cells Reduce Pain and Cartilage Degradation and Increase Immunomodulation in an Equine Osteoarthritis Model. Cartilage 2025 Jun;16(2):250-264.
    doi: 10.1177/19476035231209402pubmed: 37990503google scholar: lookup
Subscribe to our newsletter
Join 99,824 horse owners like you who receive our email updates on horse health and nutrition.